Tuesday, April 20, 2021
Home Lead Story Covaxin Shows The Efficacy Of Vaccine To Be At 81 Percent

Covaxin Shows The Efficacy Of Vaccine To Be At 81 Percent

Bharat Biotech expects to share further details of the trial results as additional data become available

Bharat Biotech on Wednesday announced the first interim analysis of Covaxin, which shows the efficacy of the Covid-19 vaccine to be at 81 percent. The Hyderabad-based vaccine maker said the whole virion inactivated Covid-19 vaccine candidate demonstrated an interim vaccine efficacy of 81 percent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with the Indian Council of Medical Research (ICMR).

“Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today’s results from our Phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants.

Follow NewsGram on Facebook to stay updated.

Covaxin demonstrates a high clinical efficacy trend against Covid-19 but also significant immunogenicity against the rapidly emerging variants,” said Dr. Krishna Ella, Chairman and Managing Director, Bharat Biotech. BBV152 (Covaxin) contains a whole virion inactivated SARS-CoV-2 vaccine, which is produced in Vero cells. It is stable at 2 to 8oC (refrigerated) and is shipped in a ready-to-use liquid formulation that permits distribution using existing vaccine supply chain channels.

BBV152 has a 28-day open vial policy as a unique product characteristic, thus reducing vaccine wastage by approximately 10-30 percent, the vaccine maker said. BBV152 is based on an established manufacturing platform with a better safety profile when compared to other vaccine platforms. The inclusion of the Algel-IMDG adjuvant enhances T-cell immune responses to Covid-19, leading to long-term protection.

covaxin
Comparison details. IANS

“I want to thank every one of the participants, who volunteered to participate in this vital clinical trial, our partners, principal investigators across 25 study sites, and our team at Bharat Biotech who dedicated their time to this vaccine discovery,” said Suchitra Ella, Joint Managing Director, Bharat Biotech.

The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of the Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) Covid-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline.

The first interim analysis is based on 43 cases, of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the BBV152 group, resulting in a point estimate of vaccine efficacy of 80.6 percent. The interim analysis included a preliminary review of the safety database, which showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups.

ALSO READ: Vaccine Acceptance Among The Indian Women Highest in The World: Harvard Study

The trial’s conduct and monitoring are as per Good Clinical Practice guidelines and have been outsourced to IQVIA. Analysis from the National Institute of Virology indicates that vaccine-induced antibodies can neutralize the UK variant strains and other heterologous strains, which has been published in bioRxiv.

Bharat Biotech expects to share further details of the trial results as additional data become available. Additional interim analysis is planned for 87 cases, and the final analysis is planned for 130 cases. All data from the second interim and final analyses will be shared via pre-publication servers as well as submitted to a peer-reviewed journal for publication, Bharat Biotech said. More than 40 countries globally have expressed their interest in Covaxin. These countries are highly satisfied with the safe, inactivated vaccine technology and robust data package for safety and immunogenicity, it added. (IANS/SP)

STAY CONNECTED

19,507FansLike
362FollowersFollow
1,773FollowersFollow

Most Popular

More Urban Indians Suffer Payment App Frauds, Card Frauds: Report

More urban Indians are facing payment app frauds (24 percent), identity thefts (20 percent), and payment card frauds (18 percent) than ever before during...

Rapprochement Between Russia And The US?

The recent announcement by the White House sources that US President Joe Biden has proposed that he and his Russian counterpart Vladimir Putin hold...

Recognize And Seize Your Serendipitous Moments: Neil J. Farber

Archimedes' discovery of the relationship of weight, volume, and density of materials, Alexander Fleming's discovery of penicillin, Samuel Morse devising the Morse code, Alexander...

Sweat Sensor Alerts Doctors And Patients To Impending Cytokine Storm In Real Time

Scientists have developed a sweat sensor that acts as an early warning system for a looming cytokine storm -- a surge of pro-inflammatory immune...

Gender-Affirming Hormone Therapy Associated With High BP Risk

Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research. Although doctors have prescribed...

Nanking Massacre: The Holocaust

By- Khushi Bisht The Nanking Massacre, also known as the Rape of Nanking, was one of the worst massacres committed during the Sino-Japanese war that...

‘Child Of Two Worlds’ Featuring The Protagonists And Immortal Lovers

Turkey-based author Ann D'Silva has launched her new book "Child of Two Worlds", which is second in the fictional 'Sand and Sea' series, which...

Now Transfer Posts And Notes To Google Docs And WordPress Directly

Facebook on Monday introducing two new data portability types that will help users directly transfer their posts and notes to Google Documents, Blogger, and...

Recent Comments